| [1] |
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med，2018，379(2):111-121.
|
| [2] |
Janni W, Nitz U, Rack BK, et al. Pooled analysis of two randomized phase Ⅲ trials (Plan B/Success C) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n＝5923) [J]. J Clin Oncol，2018，36(15 suppl):522.
|
| [3] |
Foukakis T, von Minckwitz G, Bengtsson NO，et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical crial[J]. JAMA，2016，316(18):1888-1896.
|
| [4] |
Matikas A, Foukakis T, Moebus V, et al. Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study [J]. J Clin Oncol，2018，36(15 suppl):538.
|
| [5] |
Gluz D, Nitz U, Liedtke C, et al. Impact of 12 weeks nab-paclitaxel ＋ carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase Ⅱ trial [J]. J Clin Oncol，2018，36(15 suppl):573.
|
| [6] |
Xu BH, Zhang P, Sun T，et al. Phase Ⅲ multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer [J]. J Clin Oncol，2018，36(15 suppl):1003.
|
| [7] |
Zhang P, Tong Z, Tian F, et al. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients[J]. J Hematol Oncol，2016，9(1):68.
|
| [8] |
Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial[J]. Lancet Oncol，2017，18(3):371-383.
|
| [9] |
Abramson VG, Lehmann BD, Ballinger TJ, et al. Subtyping of triple-negative breast cancer: implications for therapy[J]. Cancer，2015，121(1):8-16.
|
| [10] |
Banerji U, Dean EJ, Pérez-Fidalgo JA, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers [J]. Clin Cancer Res，2018，24(9):2050-2059.
|
| [11] |
Schmid P, Abraham J, Chan S，et al. AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase Ⅱ trial [J]. J Clin Oncol，2018，36(15 suppl):1007.
|
| [12] |
Dent R, Im SA, Espie M，et al. Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) ＋ paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC) [J]. J Clin Oncol，2018，36(15 suppl):1008.
|
| [13] |
Telli ML, Metzger O, Timms K，et al. Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin ＋/－ veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC[J]. J Clin Oncol，2018，36(15 suppl):519.
|
| [14] |
Francis PA, Pagani O, Fleming GF，et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J]. N Engl J Med，2018，379(2):122-137.
|
| [15] |
Slamon DJ, Neven P, Chia SKL，et al. Ribociclib (RIB) ＋ fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR＋), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3 [J]. J Clin Oncol，2018，36(15 suppl):1000.
|
| [16] |
Neven P, Rugo HS, Tolaney SM，et al. Abemaciclib for pre/perimenopausal women with HR＋，HER2- advanced breast cancer[J]. J Clin Oncol，2018，36(15 suppl):1002.
|
| [17] |
Kwapisz D．Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib[J]. Breast Cancer Res Treat，2017，166(1):41-54.
|
| [18] |
Jerusalem GHM, Kovalenko E, Yardley DA, et al. Everolimus (EVE) ＋ exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER＋), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study [J]. J Clin Oncol，2018，36(15 suppl):1005.
|
| [19] |
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled triall[J]. Lancet，2013，382(9897):1021-1028.
|
| [20] |
Ganz PA, Romond EH, Cecchini RS, et al. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2[J]. J Clin Oncol，2017，35(35):3942-3948.
|
| [21] |
Perez EA, Romond EH, Suman VJ，et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 [J]. J Clin Oncol，2014，32(33):3744-3752.
|
| [22] |
Pivot X, Romieu G, Debled M，et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol，2013，14(8):741-748.
|
| [23] |
Conte P, Frassoldati A, Bisagni G，et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase Ⅲ randomized Short-HER study [J]. Ann Oncol，2018. doi: 10.1093/annonc/mdy414. |
| [24] |
Cameron D, Piccart-Gebhart MJ, Gelber RD，et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet，2017，389(10 075):1195-1205.
|
| [25] |
Earl HM, Hiller L, Vallier AL，et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (＋) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results [J]. J Clin Oncol，2018，36(15 suppl): 506-506.
|
| [26] |
Baselga J, Cortés J, Kim SB，et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med，2012，366(2):109-119.
|
| [27] |
Urruticoechea A, Rizwanullah M, Im SA，et al. Final overall survival (OS) analysis of PHEREXA: A randomized phase Ⅲ trial of trastuzumab (H) ＋ capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy [J]. J Clin Oncol，2018，36(15 suppl): 1013.
|
| [28] |
Pusztai L, Hofstatter EW, Chung GG, et al. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC) [J]. J Clin Oncol，2018，36(15 suppl): 586-586.
|